Last reviewed · How we verify
IgPro20 (high dose)
IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to treat primary immunodeficiency.
IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to treat primary immunodeficiency. Used for Primary immunodeficiency disorders requiring immunoglobulin replacement therapy.
At a glance
| Generic name | IgPro20 (high dose) |
|---|---|
| Also known as | Hizentra |
| Sponsor | CSL Behring |
| Drug class | Immunoglobulin replacement therapy |
| Target | Polyclonal human IgG |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IgPro20 is a high-dose subcutaneous immunoglobulin (SCIg) preparation containing polyvalent human immunoglobulins that replaces deficient or dysfunctional antibodies in patients with primary immunodeficiency disorders. The high-dose formulation allows for less frequent dosing intervals while maintaining therapeutic immunoglobulin levels. It works by providing immediate passive immunity and helping to prevent recurrent infections in immunocompromised patients.
Approved indications
- Primary immunodeficiency disorders requiring immunoglobulin replacement therapy
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Headache
- Fatigue
- Fever
- Myalgia
Key clinical trials
- Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) (PHASE4)
- Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IgPro20 (high dose) CI brief — competitive landscape report
- IgPro20 (high dose) updates RSS · CI watch RSS
- CSL Behring portfolio CI